12:00 AM
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

arGEN-X B.V., Universite catholique de Louvain deal

arGEN-X partnered with the de Duve Institute at Universite catholique de Louvain to use arGEN-X's SIMPLE Antibody technology to validate the biology of an undisclosed cancer immunomodulation target and to...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >